Literature DB >> 30779079

Circulating microRNA array (miR-182, 200b and 205) for the early diagnosis and poor prognosis predictor of non-small cell lung cancer.

J-G Zou1, L-F Ma, X Li, F-L Xu, X-Z Fei, Q Liu, Q-L Bai, Y-L Dong.   

Abstract

OBJECTIVE: Non-small cell lung cancer (NSCLC) is the most common cause for cancer-related mortality worldwide. Currently, early detection of NSCLC is one of the main available strategies for improving its prognosis. Due to the lack of non-invasive and convenient tools, early diagnosis of NSCLC remains poor. Recently, it has been reported that circulating microRNAs (miRNAs) can be stably detected in serum. Meanwhile, they play a powerful role as biomarkers in various tumors. Therefore, the aim of this study was to detect the expression levels of serum miR-182, 200b and 205 in NSCLC patients, and to investigate their diagnostic and prognostic values. PATIENTS AND METHODS: Real-time quantitative polymerase chain reaction (RT-qPCR) was carried out to measure the expressions of miR-182, 200b and 205 in NSCLC tissues and normal controls. Receiver-operating characteristic (ROC) curve analysis was performed to assess the potential value of serum miRNAs for NSCLC diagnosis. Meanwhile, transwell assays were performed to observe the functional effects of miRNAs on the invasion and migration of NSCLC cells.
RESULTS: Compared with normal controls, serum levels of miR-182 and 205 in NSCLC patients were significantly upregulated, whereas miR-200b was remarkably downregulated. ROC analysis indicated that miRNA array (miR-182, 200b and 205) was useful biomarkers for early diagnosis of NSCLC. In addition, transwell assays demonstrated that miR-182 promoted the invasion and migration of NSCLC cells.
CONCLUSIONS: Our findings revealed that serum miR-182, 200b and 205 might serve as promising biomarkers for early detection and treatment of NSCLC.

Entities:  

Year:  2019        PMID: 30779079     DOI: 10.26355/eurrev_201902_17001

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  11 in total

1.  Long transcripts minus touchdown qPCR (LTMT-qPCR): a simplified and convenient method for the screening and quantification of microRNA profiles.

Authors:  Xi Wang; Yixiao Feng; Shixian Zhou; Xiaorong Yang; Yan Liu; Qi Peng; Xuehua Kong; Lan Zhou; Zongyue Zeng
Journal:  Lab Invest       Date:  2021-08-10       Impact factor: 5.662

Review 2.  Potential of the miR-200 Family as a Target for Developing Anti-Cancer Therapeutics.

Authors:  Hyein Jo; Kyeonghee Shim; Dooil Jeoung
Journal:  Int J Mol Sci       Date:  2022-05-24       Impact factor: 6.208

3.  Early Detection of Non-Small Cell Lung Cancer by Using a 12-microRNA Panel and a Nomogram for Assistant Diagnosis.

Authors:  Weidong Wang; Dongni Chen; Weiwei Chen; Ziya Xin; Zirui Huang; Xuewen Zhang; Kexing Xi; Gongming Wang; Rusi Zhang; Dechang Zhao; Li Liu; Lanjun Zhang
Journal:  Front Oncol       Date:  2020-06-11       Impact factor: 6.244

4.  Circulating miR-16-5p, miR-92a-3p, and miR-451a in Plasma from Lung Cancer Patients: Potential Application in Early Detection and a Regulatory Role in Tumorigenesis Pathways.

Authors:  Patricia P Reis; Sandra A Drigo; Robson F Carvalho; Rainer Marco Lopez Lapa; Tainara F Felix; Devalben Patel; Dangxiao Cheng; Melania Pintilie; Geoffrey Liu; Ming-Sound Tsao
Journal:  Cancers (Basel)       Date:  2020-07-27       Impact factor: 6.639

5.  Clinical Significance of miR-183-3p and miR-182-5p in NSCLC and Their Correlation.

Authors:  Tianxiang Zhang; Wei Li; Meng Gu; Ziyu Wang; Shijie Zhou; Xuefeng Hao; Weiying Li; Shaofa Xu
Journal:  Cancer Manag Res       Date:  2021-04-28       Impact factor: 3.989

6.  High diagnostic value of miRNAs for NSCLC: quantitative analysis for both single and combined miRNAs in lung cancer.

Authors:  Minhan Yi; Zexi Liao; Langmei Deng; Li Xu; Yun Tan; Kun Liu; Ziliang Chen; Yuan Zhang
Journal:  Ann Med       Date:  2021-12       Impact factor: 4.709

7.  Contributions of Circulating microRNAs for Early Detection of Lung Cancer.

Authors:  Jody Vykoukal; Johannes F Fahrmann; Nikul Patel; Masayoshi Shimizu; Edwin J Ostrin; Jennifer B Dennison; Cristina Ivan; Gary E Goodman; Mark D Thornquist; Matt J Barnett; Ziding Feng; George A Calin; Samir M Hanash
Journal:  Cancers (Basel)       Date:  2022-08-30       Impact factor: 6.575

Review 8.  Small RNAs, Big Diseases.

Authors:  Iwona Rzeszutek; Aditi Singh
Journal:  Int J Mol Sci       Date:  2020-08-09       Impact factor: 5.923

9.  Upregulated miR-665 expression independently predicts poor prognosis of lung cancer and facilitates tumor cell proliferation, migration and invasion.

Authors:  Jinbing Xia; Dengping Li; Xiaoliang Zhu; Wenying Xia; Zhenyong Qi; Guanhua Li; Qian Xu
Journal:  Oncol Lett       Date:  2020-03-11       Impact factor: 2.967

10.  Complement sC5b-9 and CH50 increase the risk of cancer-related mortality in patients with non-small cell lung cancer.

Authors:  Jing Li; Zhijun Cao; Lijie Mi; Zhihua Xu; Xiangmei Wu
Journal:  J Cancer       Date:  2020-10-18       Impact factor: 4.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.